Subgroup analysis by prior lines of metastatic therapy (mtx) in NAPOLI-1: A global, randomized phase 3 study of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV), vs. 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed following gemcitabine-based therapy.

Teresa Macarulla,Jens T. Siveke,Andrea Wang-Gillam,Chung-Pin Li,Gyorgy Bodoky,Andrew Peter Dean,Shan Yanshen,Gayle S. Jameson,Kyung-Hun Lee,Jean Frédéric Blanc,Chang Fang Chiu,Gilberto Schwartsmann,Fadi S. Braiteh,David Cunningham,Li-Tzong Chen,Daniel D. Von Hoff,Khalid Mamlouk,Parul Bhargava,Floris A. de Jong,Richard Hubner

Subgroup analysis by prior lines of metastatic therapy (mtx) in NAPOLI-1: A global, randomized phase 3 study of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV), vs. 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed following gemcitabine-based therapy.

2017

4127Background: In the NAPOLI-1 study, nal-IRI+5-FU/LV significantly increased median OS vs. 5-FU/LV control (6.1 vs. 4.2 mo; unstratified HR = 0.67 [0.49–0.92]; p = .012). This is a subgroup analy...

Keywords:

Fluorouracil
Oncology
Phases of clinical research
Pathology
Subgroup analysis
Gemcitabine
Liposomal Irinotecan
Adenocarcinoma
Medicine
Internal medicine
in patient
Gastroenterology
pancreatic ductal adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations